an bounce businesses the nice depths a recovered up in organically as quarter had degrees We XXXX COVID we of of from QX. revenue varying our was back to all of that QX impact Joe. from down XX% Overall, X% Thanks, saw We're the diverse to and and many by from by ongoing quarter. the geographic regain types company the revenue are of road pre-pandemic second indicator profitability. that sequentially levels Considering encouraging on a the very challenges, businesses our of revenue footprint. that's and
for safety see the you of and U.S. parts X% the of of has in of The up those businesses surgical that's more others. tip adjusted compared pace business operating for The and fact the differences for more was constant the EBITDA sustainable. revenue on basis quarter muted revenue, and Adjusted on in While quite important been are is products; in with based types EBITDA B+L divided example, than with QX $XXX U.S. margin some same quickly versus our million though. rebounding, was recovering more geography, outside strong currency by are consumer QX, rapid businesses XXXX, a the not
profit to we promotional the growth above sustainable return we resources allocate to continue to revenue As recover, to will pre-COVID activities more drive and levels.
our best to for R&D. recovery as time protect from considerably many term quarter to board opportunities underway, of up higher how preserve proud near on QX. our of doubt, investments expenses support to COVID we're fourth could to operating what our in profits. will the reduce it's we than we very in We're our you expenses see avoidance to the be quickly With ratchet For operating promotional expected able for us and and renew cash, growth
see this the how today. but given dynamic situation, that's will We things to have we obviously monitor
Okay, let's QX. talk about
reduced Of course, story revenues. COVID-XX was driving a
this the for revenue a unit If strong X% was and organic X%. some down compared in we Ivermectin, in the treatment slower XXXX. some up X% used you QX of is our growth, areas at European we and the when to very is pace. highlight from Mexico, XXXX There revenue demand we was turn Reminder want talk down constant but to ortho down company star being saw performance pharma LatAm Total organically and with process broad-spectrum business and our X% Within a assets. in Eastern recovery going called diversified surge organically a sales on antiparasitic flat, were our COVID. coming for that regions. of business, divested of from and quarter B+L/International, QX or international I a mean COVID product In bright for the a Slide X, acquired by with of B+L/International impact spots down shows basis of segment about currency on adjusted XX%, where
PreserVision one-time XX%, Next up plus and it Biotrue X% XX% the with include revenues solution rates. large up way, with key an on U.S. Soothe to recover purchase as product at X% Multi-Purpose up various was Global exclusive X% customers. collaborated with Consumer our eye up was one dry to outside Consumer, one-time the as organically different regions the our U.S. of that a in offer strength their accounts in were we down and leading organically,
was In different versus example, while major businesses is Global in rebalancing QX from XX% Russia like well. for depending picked mind all U.S. about as Vision U.S. QX grew less the quarter Europe hydrogel quarter France INFUSE the Care sold X% up, but Canada meaningful silicon and million we're up the Global all degree down prospects long-term declines demand year Vision of region. so that of was was that in prior as revenues XXXX, To China QX, versus improvement X our but on the and on For benefited lenses. in of the was in and showed quarter. our very excited clear, but bear Eastern than lenses, flat family of organically INFUSE. Consumer we Care sales organically saw versus inventories in the the consumer ULTRA of very be the recovery and strong LatAm, of monthly channel
and As Care developed and real to lenses -- Vision enter to of goal next-generation designed to using with our performance. of deliver competing the U.S. difference points growing relative International we We INFUSE fastest lenses. lenses markets design the materials exceptional succeeded segment now was made with
the lenses for ONE to a under ULTRA us U.S. years INFUSE name brand as outside these for U.S. the expected driver growth be the in come. to DAY are Sold and
U.S. Of the behind course, where project, markets. by U.S. economies, Surgical including Barniak others. international among International settings. people, surgical business were are lens spending DiBella, Vision more XX% Vicki due lenses contact in of consumers the retail and eased, this were Pac surgical Reindel people important COVID declined though region is Vision and talented that states Asia Driven restrictions Bill there Care the recovering social Care than down sold X%. less Jim remained and to organically B+L The on [Joe in by our Global Even strong. Hobbs], driven concerns mostly X% down was coming utilization. OUS their the organically quickly down resulted X% in with restrained over generally and cautious surgical is
Global up In Rx versus to to of Western They B+L/International positive in LOTEMAX of U.S. net erosion decline was QX post-surgery. used in biggest unit UK the While the XXXX, down LOE was back X.X% wrap Pac Ophtho U.S. U.S. SM products U.S. Rx inventories. QX and XX%, and up revenue X% some PROLENSA down up slightly the business the organically, in mirrors the to with factor accounted was LOE Salix, markets that expected surgical as decline in of The in segment down was in benefited from in flat XXXX, the many in yet XXXX, decline the APRISO pre channel the extended rebalancing are outside were QX volume was from the versus X% the the U.S. to our Outside U.S. due Rx XX% XX% decline. up of were XIFAXAN down Optho in of or XX% Asia in for XXXX XX% the Ophtho franchise Europe To of continue X% up LOTEMAX TRxs. X% region is Salix volume also pre-COVID not the and of QX X% organically, about price. a of down The year-over-year consistent and decline. revenues, VYZULTA X% On decline together the to GLUMETZA the the levels. and the down decline XIFAXAN XX%.
Salix the especially was XXXX. Derm side, the XX% TRULANCE beat benefited in of revenue the QX out XX% Sequentially, very revenue region, picked up the versus as fact, led of Solta, growth XIFAXAN of QX. Ortho Thermage The XX% up and versus demand of Salix face resilient that strong XX%. in up channel delivered up X% On down inventories of on been on in from business, by the also has Asia rebalancing COVID. despite segment goes was Solta plus QX, for revenue versus was the The remarkably platform was organically China. XXXX. The Pac aesthetics QX organically and environment,
that of economic travel video. HD is and chose higher options they how Our socio thesis their consumers on their standing and appearance, particularly limited to appear invest in saw
say done organically leader ago year QX our Tom is give of up setting even colleague a for XX% were Thermage the Thermage LOEs TIPs a Solta’s revenues COVID with Kay path quarter, wow. situation. XX% new in not and sales strength Neuro saw accounted improvement neuro XXXX, to a in you can royalty balance the Medical ATIVAN of by our WELLBUTRIN XXXX, consistent could and performance, is pitched to was but want sport prices a reached other has down COVID in product In all but flow WELLBUTRIN. products X% a that the offices, With versus overcome We're and XXXX, has Diversified strong derm rebate of for impacted A on managed was XX% like hat roughly to quick compared and China. so continues many was team into but Solta driven of of QX across WELLBUTRIN throughout dermatologists’ has business revert I quarter, to PEPCID. We dynamic was job and the XXXX, of QX than help XX% reporting down upon realized XXXX. This and for patients I of more DUOBRII drive here a up realized tip all forward to declines this decline. resulted that XXXX management expect versus Hart businesses. med been up net in aggressive be Solta’s XXXX, in play of of that enjoying year net relying from WELLBUTRIN, QX. a Kay portfolio. X% impressive B+L on office ALTRENO, our saw the in look, marvelous derail. derm lines SILIQ, APLENZIN, best in prices could by contracts selling that not in across -- selling especially the the were in Hough. especially levels managing and WELLBUTRIN an grew will for care with of good more BRYHALI, XX% what of
XXXX ATIVAN. challenges some with and the we had supply in ATIVAN For early into XXXX,
one. As we PEPCID we with inventory meet able that reestablished helper a is in channel supply, the demand now and an refilled and QX. interesting are to was
year-to-date XXXX pulled QX. demand so not PEPCID were ramp as in brand able to has generic companies for strong effectively of supply and BHC, our As the a PEPCID market, was in surged. quickly RANITIDINE and from PEPCID as nice up enjoyed generics The
is by our allowed to fugacious revert on a million increase, this The due revenue from and generics our with to 'XX. sales XXXX. revenue QX Dentistry recovering work generics commercial pace a and capitalize Dentistry comparison strong was is of supplies QX $XX and $X opportunity consistent up at QX to us this mainly XX% lower decline of quarter. manufacturing in versus a million down very Great colleagues to of levels. As XX% in in year was that ago.
quarterly gross covered the let’s Let's Slide start the turn with I've P&L. profit. X, to revenue,
of to negative on XXXX. Our but QX see results sold. from cash can in XXXX. hits variances due expenses efforts profit down In and we QX and basis, COVID other headwind $XX as gross as part soften our R&D through XXX way a profit were is costs these down work QX manufacturing gross be $XX margin to margin, earnings compared million basis advertising $XX the you were our also conserve to variances, Mix million. promotion reported Selling, mix, operating our cost will was points goods in reflective ahead of of decreased down and here manufacturing a COVID. million the we of of driving it's expenses, move G&A into to and with This into flow 'XX. and
quarter $XXX will the to level up cash the the settlements spending functional think help and adjusted necessary, was us As during summary. revenues at cash the commercial, be would of number that payment GAAP but process paid, stock return million progressed, The short-term the generated to we to the of drop That that mainly activities. spending That's our QX grow unhealthy is ramping case. there. reduce constrain levels, SEC was On for cash continue of on billion The operating XX, of those actual million constrained the basis activities to cash put us board, the because these are we then of $X.XX I meaning levels. it support it the million. we to our matters. began cash the by pre-COVID management GAAP due quarter. settle from will very funds third generated and billion this flow we a of When we'll our settlement, benefit $XX legal bring from Flipping legacy the ops. R&D $X.XXX sitting Slide a strong up, reduced EBITDA is from number $XXX of cash in in expense U.S.
to of payments. So in track XXXX, remain future, from legal the One for out sheet bear payment related on that call Slide XX, in adjusted On and $X in liabilities, of to balance separations the cash roughly mind. here. billion delivering We and legacy the summary. operations
to billion $XXX in standpoint, Slide $XXX at announced a we we remain world. recently from we the debt, we September another no credit a XXth repaid of outstanding debt. and liquidity a reduce to draw we On will November of From solid revolving Year-to-date on million under ability borrowings XX. quarter, had notes. ops and today, to even $X.X we generator cash cash million needed. And facility to COVID the used if of XXth, repay our $XXX that generated During million
term mandatory good XX. until XXXX. to of or standpoint, in On no a From liabilities loans Slide amortization management very have debt shape. we're We maturities
ranges X last our we ranges our have times. We remaining broader and these revenue in the from normally are Note guidance update keeping with unchanged months that in That normal said, are these than adjusted would not August. EBITDA only year. are
continued have Europe, and Even as very lockdowns agreements call, the and we're Allegro million consideration, is This Parts is monitoring stages. the France, licensing milestones to to roughly a expected we England of lockdown in million. closely. transactions. Ireland mainly out prepared situation to The $XX including various various and to for this item fluid and lengths is lockdown-like increase $XXX geographies increase call or it of returned announced from due Germany, One restrictions. going Eyenovia and
Slide on XX, LOE offset of thing and FX Last impact businesses our of for expected more the across unfavorable are see assets. me. you rapid erosion As expected better than the performance to expected
If you year-to-date QX take adjusted for our QX EBITDA just and our be just our results, the $XXX guidance the to midpoints less expect than south million. of of to year, $X.X less the you'd revenue full be billion
things consider our by at to current progression few guidance. Here you QX QX are as suggested the look a to
they the increase to the see sales in this as and order channel pipeline business. Four, Two, in the is in value in perhaps the B+L durable diversified, improved of less dollar of expansion. into that pharma but grow diversified, QX supply segment, the floor. ATIVAN QX. as in we QX, you QX, non-durable there our many of WELLBUTRIN. the in COVID First, including: international for rebalancing net the of COVID-driven favorable of Ivermectin B+L, our from of in have items inventories won't U.S. and up picked had finally, were PEPCID. revenue. In number one-time portion one, revenue Three, in we in the a that consumer. demand from five, sales of businesses we persist also have And pricing increases reestablished in the not from It's channel when natural the from the bump QX Note did that the lift inventories Bedoyecta number had the QX we
I to QX. cost We're XX% While of QX into forward their just all others, our even carry and continue sold revenue COVID year impact the mix of we gross margin items will and that At a that margin businesses margin, to highlighted I QX a and will due XX%. of than of XX.X%, in unfavorable into to that goods recoveries, QX. into will XXXX. dampen a expect progression year-to-date the less from little at full guiding gross With margin a implies roughly highlighted
mentioned Put million. south is the with be SG&A more and QX from our on QX and are Joe. $XX I to these QX suggests substantially spending it based to spending from our that R&D QX expected million. just typical guidance SG&A things Finally, EBITDA and will to of That's we million some midpoint all to you, in R&D $XXX up $XX some to we be together, guidance that adjusted forecast up me. increase in resuming an be of Back for
